“We have been advancing the industry with innovative preservation approaches for over two decades,” says David Plimpton, CEO and President of INOLEX, in his recent remarks to the press. “This latest patent demonstrates our leadership in this category. Our broad portfolio of CHA offerings exemplifies our drive to bring effective alternative preservation mainstream.”
INOLEX secures US Patent 10,897,899 for CHA-diol compositions in beauty and wellness products
INOLEX specializes in sustainable plant-based specialty ingredients for the health, wellness, and beauty industries. And in know in the cosmetics and personal care space for its biodegradable sun care polymers, silicone alternatives, palm oil alternatives, quat-free cationic conditioning agents, and alternative preservation systems.
This latest innovation in product preservation follows on the heels of the final report of the Cosmetic Ingredient Review (CIR) regarding the safe use of CHA or caprylhydroxamic acid. The newly patented technology is basically the combining of CHA and any one of several medium-chain, terminal diols.
As the company’s recent media release announcing the US patent, “Caprylhydroxamic acid is a 100% natural and readily biodegradable chelating agent derived from coconut-sourced caprylic acid. CHA is a biostatic ingredient that provides a strong hurdle to microbial growth across a wide pH range (pH 4-8).”
And the release goes on to cursorily describe the technology’s function as a beauty product preservation system: “Robust broad-spectrum protection against contamination by bacteria, yeast, and mold is achieved via combination of CHA with medium chain terminal diols, such as caprylyl glycol, glyceryl caprylate, or caprylyl glyceryl ether.”
Beauty ingredient makers share data in the interest of consumer safety
To ensure that the independent Expert Panel for Cosmetic Ingredient Safety at the CIR (a non-profit funded by the Personal Care Products Council) had all the information needed to make its safety determination regarding CHA, INOLEX shared its own data and undertook supplementary clinicals as Dr. Michael Fevola, Vice President of R&D at INOLEX explains in comments included in the recent company press release about the preservation tech patent:
“We proactively contributed our entire archive of safety and toxicological data on CHA for the benefit of our customers and their consumers,” says Fevola. “INOLEX also commissioned additional clinical safety studies and a quantitative risk assessment as requested by the Expert Panel to validate CHA safety at all use levels reported by CIR,” he says, taking care to note that ““As a company we have established high safety and transparency standards for all of our technologies.”